1. シグナル伝達
  2. GPCR/G Protein
  3. LPL Receptor
  4. LPAR2 Isoform

LPAR2

LPAR2 (lysophosphatidic acid receptor 2) is a G protein-coupled receptor for lysophosphatidic acid (LPA) that couples predominantly to Gi/o, Gq, and G12/13 signaling pathways, thereby regulating cell survival, apoptosis resistance, migration, cytokine production, and other context-dependent cellular responses[1][5]. LPAR2 functions within the broader LPA-LPAR signaling network, but it is particularly associated with pro-survival signaling and inhibition of apoptosis, distinguishing it from receptor subtypes such as LPAR1, which are more strongly linked to cell motility and invasion[5][2]. Mechanistically, LPAR2 contains a distinctive C-terminal protein-interaction region that enables binding to scaffold proteins including NHERF2 and MAGI-3, creating receptor-specific signaling complexes that modulate downstream pathways such as ERK, Akt, RhoA, phospholipase C, NF-κB, and JNK signaling[3]. In disease models, elevated LPAR2 expression has been reported in several malignancies, including colorectal, ovarian, breast, thyroid, and endometrial cancers, where LPAR2 signaling contributes to proliferation, survival, migration, invasion, inflammatory mediator production, and tumor progression[2][4]. Experimental studies further demonstrate that genetic deletion or suppression of LPAR2 attenuates tumor-promoting and inflammatory responses in colorectal cancer models, supporting its utility as a mechanistic target for cancer biology research[4][6]. Compared with related isoforms, the unique PDZ-domain-mediated signaling architecture of LPAR2 provides an important experimental framework for dissecting receptor-specific functions within the LPA signaling system[3]. For experimental applications, selective modulation of LPAR2 activity has been used to investigate cancer-associated signaling, apoptosis regulation, cell migration, and inflammation-related pathways[2][4].

LPAR2 関連製品 (6):

製品番号 製品名 製品効果 純度
  • HY-107616
    H2L5186303 Antagonist 98.50%
    H2L5186303 is a potent and selective LPA2 receptor antagonist with an IC50 of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects.
  • HY-100676
    GRI977143 Agonist 99.29%
    GRI977143 is a specific LPA2 receptor agonist, with an EC50 of 3.3 μM .
  • HY-178845
    Decyl phosphate Modulator
    Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders.
  • HY-118539
    NSC12404 Agonist
    NSC12404 is a weak and specific LPA2 receptor agonist.
  • HY-148291
    BrP-LPA sodium Antagonist
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.
  • HY-W725737
    BrP-LPA Antagonist
    BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior.